FDA approval of EKTERLY makes KalVista Pharmaceuticals, Inc. the first to offer an oral on-demand HAE therapy, providing a major competitive advantage over injectable options. EKTERLY’s convenience ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback